Cross protective immune responses in mice elicited by prime-boost strategy with a recombinant DNA vaccine and adenoviral 5-based vaccine expressing structural antigens of hepatitis C virus
10.3760/cma.j.issn.0254-5101.2016.03.011
- VernacularTitle:基于丙型肝炎病毒结构基因的DNA疫苗初免重组腺病毒疫苗加强免疫小鼠后可诱导交叉保护
- Author:
Yao DENG
;
Jie GUAN
;
Xiao YIN
;
Jiaming LAN
;
Hong CHEN
;
Wen WANG
;
Wenjie TAN
- Publication Type:Journal Article
- Keywords:
Hepatitis C virus;
DNA vaccine;
rAd5-based vaccine;
T cell response;
Prime-boost vaccination
- From:
Chinese Journal of Microbiology and Immunology
2016;36(3):219-223
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the development strategy of novel T cell based vaccine against HCV infection.Methods BALB/c mice were primed with pSCK-based DNA vaccine and boosted with type 5 adenoviral vector-based vaccine, which expressed the structural proteins ( Core, E1 and E2) de-rived from a Chinese HCV patient (genotype 1b, Hebei strain).Enzyme linked immunospot assay (ELIS-POT) and intracellular cytokine staining ( ICS) were used to analyze the elicited antigen-specific immune re-sponses and the efficacy of cross-protection.Results Immunization of mice with the prime-boost vaccination strategy elicited stronger T cell immune responses against multiple HCV antigens than using the DNA vac-cines alone, especially the IFN-γ-secreting T cell responses against E1 protein as indicated by ELISPOT as-say.ICS data indicated that the prime-boost regimen elicited more TNF-α-producing CD4+and IFN-γ-produ-cing CD8+T cells against E1 protein and high levels of IFN-γ-producing CD4+and CD8+T cells against E2 protein in comparison with immunization with DNA vaccines.Moreover, the prime-boost vaccination was ca-pable of eliciting effective cross-protection in a surrogate challenge model based on a recombinant heterolo-gous HCV (JFH1, 2a) vaccinia virus.Conclusion The prime-boost vaccination using DNA and rAd5-based vaccine expressing HCV structural antigens induced significant cellular immune response and cross-protection in mice, suggesting the possibility of using it as a promising T cell based vaccine against HCV in-fection.
